Novartis' Phase 3 NETTER-2 Trial With Lutathera Met The Primary Endpoint Of Improvement In Progression-free Survival In Advanced Gastroenteropancreatic Neuroendocrine Tumors
Portfolio Pulse from Benzinga Newsdesk
Novartis' Phase 3 NETTER-2 trial with Lutathera has met the primary endpoint of improvement in progression-free survival in advanced gastroenteropancreatic neuroendocrine tumors.
September 25, 2023 | 9:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis' successful Phase 3 trial of Lutathera could potentially lead to increased revenues from the drug's sales.
The successful completion of the Phase 3 trial indicates that Lutathera is effective in treating advanced gastroenteropancreatic neuroendocrine tumors. This could lead to increased sales of the drug, thereby potentially boosting Novartis' revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100